ID: ALA15245

Max Phase: Approved

Molecular Formula: C21H26N2O3

Molecular Weight: 354.45

Molecule Type: Small molecule

Representations

Synonyms (2): Yohimbine | Yohimbinum
Synonyms from Alternative Forms(2):

Canonical SMILES:  COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O

Standard InChI:  InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1

Standard InChI Key:  BLGXFZZNTVWLAY-SCYLSFHTSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Properties

Molecular Weight: 354.45

Molecular Weight (Monoisotopic): 354.1943

AlogP: 2.65

#Rotatable Bonds: 1

Polar Surface Area: 65.56

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.22

CX LogP: 2.10

CX LogD: 1.88

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.77

Np Likeness Score: 1.17

References

1. Miller DD, Hamada A, Clark MT, Adejare A, Patil PN, Shams G, Romstedt KJ, Kim SU, Intrasuksri U, McKenzie JL..  (1990)  Synthesis and alpha 2-adrenoceptor effects of substituted catecholimidazoline and catecholimidazole analogues in human platelets.,  33  (4): [PMID:2157007] [10.1021/jm00166a009]

2. Strobl GR, von Kruedener S, Stöckigt J, Guengerich FP, Wolff T..  (1993)  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.,  36  (9): [PMID:8487254] [10.1021/jm00061a004]

3. Saari WS, Halczenko W, Huff JR, Guare JP, Hunt CA, Randall WC, Lotti VJ, Yarbrough GG..  (1984)  Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.,  27  (9): [PMID:6088770] [10.1021/jm00375a017]

4. DeMarinis RM, Hieble JP..  (1983)  l-1,2,3,4-Tetrahydro-8-methoxy-5-(methylthio)-2-naphthalenamine: a potent and selective agonist at alpha 1-adrenoceptors.,  26  (9): [PMID:6136611] [10.1021/jm00363a002]

5. Van Dort M, Neubig R, Counsell RE..  (1987)  Radioiodinated p-iodoclonidine: a high-affinity probe for the alpha 2-adrenergic receptor.,  30  (7): [PMID:3037080] [10.1021/jm00390a021]

6. Caroon JM, Clark RD, Kluge AF, Nelson JT, Strosberg AM, Unger SH, Michel AD, Whiting RL..  (1981)  Synthesis and antihypertensive activity of a series of 8-substituted 1-oxa-3,8-diazaspiro[4.5]decan-2-ones.,  24  (11): [PMID:7310808] [10.1021/jm00143a012]

7. Vizi ES, Toth I, Somogyi GT, Szabo L, Harsing LG, Szantay C..  (1987)  Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.,  30  (8): [PMID:2886664] [10.1021/jm00391a015]

8. Guérémy C, Audiau F, Renault C, Benavides J, Uzan A, Le Fur G..  (1986)  4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.,  29  (8): [PMID:3016265] [10.1021/jm00158a013]

9. Timmermans PB, van Zwieten PA..  (1982)  alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs.,  25  (12): [PMID:6296387] [10.1021/jm00354a001]

10. Marciniak G, Delgado A, Leclerc G, Velly J, Decker N, Schwartz J..  (1989)  New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.,  32  (6): [PMID:2542561] [10.1021/jm00126a042]

11. Ward TJ, White JF, Lattimer N, Rhodes KF, Sharma S, Waterfall JF..  (1988)  Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.,  31  (7): [PMID:2838634] [10.1021/jm00402a029]

12. Wentland MP, Bailey DM, Alexander EJ, Castaldi MJ, Ferrari RA, Haubrich DR, Luttinger DA, Perrone MH..  (1987)  Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.,  30  (8): [PMID:3039138] [10.1021/jm00391a034]

13. Foulon C, Kung MP, Kung HF..  (1993)  Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.,  36  (10): [PMID:8098771] [10.1021/jm00062a025]

14. Hlasta DJ, Luttinger D, Perrone MH, Silbernagel MJ, Ward SJ, Haubrich DR..  (1987)  Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.,  30  (9): [PMID:2887657] [10.1021/jm00392a005]

15. Andrews PR, Craik DJ, Martin JL..  (1984)  Functional group contributions to drug-receptor interactions.,  27  (12): [PMID:6094812] [10.1021/jm00378a021]

16. Saari WS, Halczenko W, King SW, Huff JR, Guare JP, Hunt CA, Randall WC, Anderson PS, Lotti VJ, Taylor DA..  (1983)  Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.,  26  (12): [PMID:6139479] [10.1021/jm00366a007]

17. Huff JR, Anderson PS, Baldwin JJ, Clineschmidt BV, Guare JP, Lotti VJ, Pettibone DJ, Randall WC, Vacca JP..  (1985)  N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.,  28  (12): [PMID:2999400] [10.1021/jm00150a002]

18. Suomalainen P, Johans C, Söderlund T, Kinnunen PK..  (2004)  Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,  47  (7): [PMID:15027870] [10.1021/jm0309001]

19. Clark RD, Repke DB, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M..  (1989)  (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.,  32  (9): [PMID:2570150] [10.1021/jm00129a002]

20. Berglund J, Nicholls IA, Lindbladh C, Mosbach K.  (1996)  Recognition in molecularly imprinted polymer 2-adrenoreceptor mimics,  6  (18): [10.1016/0960-894X(96)00406-4]

21. Chumpradit S, Kung MP, Billings J, Mach R, Kung HF..  (1993)  Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.,  36  (2): [PMID:8093734] [10.1021/jm00054a005]

22. Audia JE, Evrard DA, Murdoch GR, Droste JJ, Nissen JS, Schenck KW, Fludzinski P, Lucaites VL, Nelson DL, Cohen ML..  (1996)  Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.,  39  (14): [PMID:8709108] [10.1021/jm960062t]

23. Perrone R, Berardi F, Leopoldo M, Tortorella V, Fornaretto MG, Caccia C, McArthur RA..  (1996)  1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.,  39  (16): [PMID:8759642] [10.1021/jm960087s]

24. Hieble JP, Bondinell WE, Ruffolo RR..  (1995)  Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.,  38  (18): [PMID:7658428] [10.1021/jm00018a001]

25. Mayer P, Brunel P, Chaplain C, Piedecoq C, Calmel F, Schambel P, Chopin P, Wurch T, Pauwels PJ, Marien M, Vidaluc JL, Imbert T..  (2000)  New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.,  43  (20): [PMID:11020279] [10.1021/jm991121g]

26. Ruffolo RR, Bondinell W, Hieble JP..  (1995)  Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.,  38  (19): [PMID:7562902] [10.1021/jm00019a001]

27. McNeal ET, Lewandowski GA, Daly JW, Creveling CR..  (1985)  [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.,  28  (3): [PMID:2579237] [10.1021/jm00381a019]

28. Perrone R, Berardi F, Colabufo NA, Leopoldo M, Tortorella V, Fornaretto MG, Caccia C, McArthur RA..  (1996)  Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.,  39  (25): [PMID:8960552] [10.1021/jm9604538]

29. Timmermans PB, de Jonge A, Thoolen MJ, Wilffert B, Batink H, van Zwieten PA..  (1984)  Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.,  27  (4): [PMID:6142954] [10.1021/jm00370a011]

30. Belliotti TR, Wustrow DJ, Brink WA, Zoski KT, Shih YH, Whetzel SZ, Georgic LM, Corbin AE, Akunne HC, Heffner TG, Pugsley TA, Wise LD..  (1999)  A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.,  42  (25): [PMID:10602703] [10.1021/jm990277d]

31. Chapleo CB, Myers PL, Butler RC, Davis JA, Doxey JC, Higgins SD, Myers M, Roach AG, Smith CF, Stillings MR..  (1984)  Alpha-adrenoreceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on alpha-adrenoreceptor activity.,  27  (5): [PMID:6143826] [10.1021/jm00371a003]

32. Klein JT, Davis L, Olsen GE, Wong GS, Huger FP, Smith CP, Petko WW, Cornfeldt M, Wilker JC, Blitzer RD, Landau E, Haroutunian V, Martin LL, Effland RC..  (1996)  Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.,  39  (2): [PMID:8558529] [10.1021/jm9506433]

33. Clark RD, Berger J, Garg P, Weinhardt KK, Spedding M, Kilpatrick AT, Brown CM, MacKinnon AC..  (1990)  Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.,  33  (2): [PMID:2153820] [10.1021/jm00164a021]

34. Zheng W, Lei L, Lalchandani S, Sun G, Feller DR, Miller DD..  (2000)  Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors.,  10  (7): [PMID:10762040] [10.1016/s0960-894x(00)00068-8]

35. Caroon JM, Clark RD, Kluge AF, Olah R, Repke DB, Unger SH, Michel AD, Whiting RL..  (1982)  Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.,  25  (6): [PMID:6124635] [10.1021/jm00348a012]

36. Clark RD, Repke DB, Berger J, Nelson JT, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M..  (1991)  Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.,  34  (2): [PMID:1671705] [10.1021/jm00106a036]

37. Chapleo CB, Myers PL, Butler RC, Doxey JC, Roach AG, Smith CF..  (1983)  alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.,  26  (6): [PMID:6133953] [10.1021/jm00360a008]

38. Kemp CA, Flanagan JU, van Eldik AJ, Maréchal JD, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ..  (2004)  Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.,  47  (22): [PMID:15481972] [10.1021/jm049934e]

39. Mustafa SM, Bavadekar SA, Ma G, Moore BM, Feller DR, Miller DD..  (2005)  Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptors.,  15  (11): [PMID:15911252] [10.1016/j.bmcl.2005.03.116]

40. Minetti P, Tinti MO, Carminati P, Castorina M, Di Cesare MA, Di Serio S, Gallo G, Ghirardi O, Giorgi F, Giorgi L, Piersanti G, Bartoccini F, Tarzia G..  (2005)  2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.,  48  (22): [PMID:16250647] [10.1021/jm058018d]

41. Cesari N, Biancalani C, Vergelli C, Dal Piaz V, Graziano A, Biagini P, Ghelardini C, Galeotti N, Giovannoni MP..  (2006)  Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.,  49  (26): [PMID:17181165] [10.1021/jm060743g]

42. Giovannoni MP, Cesari N, Vergelli C, Graziano A, Biancalani C, Biagini P, Ghelardini C, Vivoli E, Dal Piaz V..  (2007)  4-amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action.,  50  (16): [PMID:17629262] [10.1021/jm070161e]

43. Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP..  (2008)  Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.,  51  (14): [PMID:18588282] [10.1021/jm701575k]

44. Gafner S, Dietz BM, McPhail KL, Scott IM, Glinski JA, Russell FE, McCollom MM, Budzinski JW, Foster BC, Bergeron C, Rhyu MR, Bolton JL..  (2006)  Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,  69  (3): [PMID:16562853] [10.1021/np058114h]

45. Itoh A, Kumashiro T, Yamaguchi M, Nagakura N, Mizushina Y, Nishi T, Tanahashi T..  (2005)  Indole alkaloids and other constituents of Rauwolfia serpentina.,  68  (6): [PMID:15974606] [10.1021/np058007n]

46. Itoh A, Kumashiro T, Yamaguchi M, Nagakura N, Mizushina Y, Nishi T, Tanahashi T..  (2005)  Indole alkaloids and other constituents of Rauwolfia serpentina.,  68  (6): [PMID:15974606] [10.1021/np058007n]

47. Mroue MA, Euler KL, Ghuman MA, Alam M.  (1996)  Indole Alkaloids of Haplophyton crooksii 1 ,  59  (9): [10.1021/np960070c]

48. Jain KS, Bariwal JB, Kathiravan MK, Phoujdar MS, Sahne RS, Chauhan BS, Shah AK, Yadav MR..  (2008)  Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.,  16  (9): [PMID:18378462] [10.1016/j.bmc.2008.02.091]

49. Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ..  (2005)  Molecular basis of inverse agonism in a G protein-coupled receptor.,  1  (1): [PMID:16407989] [10.1038/nchembio705]

50. PubChem BioAssay data set, 

51. PubChem BioAssay data set, 

52. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD..  (2008)  cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.,  51  (22): [PMID:18983139] [10.1021/jm8007618]

53. Hayashi S, Nakata E, Morita A, Mizuno K, Yamamura K, Kato A, Ohashi K..  (2010)  Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.,  18  (21): [PMID:20875743] [10.1016/j.bmc.2010.07.034]

54. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

55. Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J, Frédérick R..  (2011)  Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.,  54  (15): [PMID:21726069] [10.1021/jm2006782]

56. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS..  (2001)  Rational use of in vitro P-glycoprotein assays in drug discovery.,  299  (2): [PMID:11602674]

57. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

58. Sun H..  (2012)  Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.,  22  (2): [PMID:22197392] [10.1016/j.bmcl.2011.12.005]

59. Mammoli V, Bonifazi A, Del Bello F, Diamanti E, Giannella M, Hudson AL, Mattioli L, Perfumi M, Piergentili A, Quaglia W, Titomanlio F, Pigini M..  (2012)  Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.,  20  (7): [PMID:22370341] [10.1016/j.bmc.2012.02.016]

60. Del Bello F, Diamanti E, Giannella M, Mammoli V, Marchioro C, Mattioli L, Titomanlio F, Piergentili A, Quaglia W, Benedetti G, Varrone M, Pigini M..  (2012)  Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.,  3  (7): [PMID:24900506] [10.1021/ml300064v]

61. Lachance H, Wetzel S, Kumar K, Waldmann H..  (2012)  Charting, navigating, and populating natural product chemical space for drug discovery.,  55  (13): [PMID:22537178] [10.1021/jm300288g]

62. Giorgioni G, Accorroni B, Di Stefano A, Marucci G, Siniscalchi A, Claudi F.  (2005)  Benzimidazole, Benzoxazole and Benzothiazole Derivatives as 5HT2B Receptor Ligands. Synthesis and Preliminary Pharmacological Evaluation,  14  (2): [10.1007/s00044-005-0125-z]

63. PubChem BioAssay data set, 

64. Veinberg G, Vorona M, Zvejniece L, Vilskersts R, Vavers E, Liepinsh E, Kazoka H, Belyakov S, Mishnev A, Kuznecovs J, Vikainis S, Orlova N, Lebedev A, Ponomaryov Y, Dambrova M..  (2013)  Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,  21  (10): [PMID:23582449] [10.1016/j.bmc.2013.03.016]

65. Germain AR, Carmody LC, Nag PP, Morgan B, Verplank L, Fernandez C, Donckele E, Feng Y, Perez JR, Dandapani S, Palmer M, Lander ES, Gupta PB, Schreiber SL, Munoz B..  (2013)  Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,  23  (6): [PMID:23403082] [10.1016/j.bmcl.2013.01.025]

66. Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G, Giorgi G, Mennuni L, Lanza M, Giordani A, Caselli G, Letari O, Makovec F..  (2013)  Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.,  63  [PMID:23466604] [10.1016/j.ejmech.2013.01.044]

67. Unpublished dataset, 

68. Rajagopalan R, Bandyopadhyaya A, Rajagopalan DR, Rajagopalan P..  (2014)  The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.,  24  (2): [PMID:24365159] [10.1016/j.bmcl.2013.12.024]

69. Kołaczkowski M, Marcinkowska M, Bucki A, Pawłowski M, Mitka K, Jaśkowska J, Kowalski P, Kazek G, Siwek A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P..  (2014)  Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.,  57  (11): [PMID:24805037] [10.1021/jm401895u]

70. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

71. Kołaczkowski M, Marcinkowska M, Bucki A, Śniecikowska J, Pawłowski M, Kazek G, Siwek A, Jastrzębska-Więsek M, Partyka A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P..  (2015)  Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,  92  [PMID:25557493] [10.1016/j.ejmech.2014.12.045]

72. PubChem BioAssay data set, 

73. Waszkielewicz AM, Gunia-Krzyżak A, Powroźnik B, Słoczyńska K, Pękala E, Walczak M, Bednarski M, Żesławska E, Nitek W, Marona H..  (2016)  Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.,  24  (8): [PMID:26988801] [10.1016/j.bmc.2016.03.006]

74. WHO Anatomical Therapeutic Chemical Classification, 

75. Gunia-Krzyżak A, Żelaszczyk D, Rapacz A, Żesławska E, Waszkielewicz AM, Pańczyk K, Słoczyńska K, Pękala E, Nitek W, Filipek B, Marona H..  (2017)  Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3.,  25  (2): [PMID:27876250] [10.1016/j.bmc.2016.11.014]

76. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T..  (2012)  Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.,  40  (12): [PMID:22961681] [10.1124/dmd.112.047068]

77. Unpublished dataset, 

78. Norwood VM, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW..  (2020)  Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.,  63  (10): [PMID:31913038] [10.1021/acs.jmedchem.9b01924]

79. Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, León F, Hiranita T, Avery BA, McMahon LR, McCurdy CR..  (2020)  Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.,  63  (1): [PMID:31834797] [10.1021/acs.jmedchem.9b01465]

80. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

81. Paciaroni NG,Norwood VM,Ratnayake R,Luesch H,Huigens RW.  (2020)  Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.,  28  (14): [PMID:32616180] [10.1016/j.bmc.2020.115546]

82. Kamboj A, Sihag B, Brar DS, Kaur A, Salunke DB..  (2021)  Structure activity relationship in β-carboline derived anti-malarial agents.,  221  [PMID:34058709] [10.1016/j.ejmech.2021.113536]

83. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(8):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• DrugMatrix
• Gene Expression Atlas Compounds
• AstraZeneca Deposited Data
• WHO Anatomical Therapeutic Chemical Classification
• IMI-CARE SARS-CoV-2 Data